Fiche publication
Date publication
mars 2023
Journal
Bioconjugate chemistry
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BETTAIEB Ali
,
Pr PAUL Catherine
,
Pr DENAT Franck
,
Dr COLLIN Bertrand
,
Dr BELLAYE Pierre-Simon
Tous les auteurs :
Privat M, Bellaye PS, Chazeau E, Racoeur C, Adumeau P, Vivier D, Bernhard C, Moreau M, Collin B, Bettaieb A, Denat F, Bodio E, Paul C, Goze C
Lien Pubmed
Résumé
Among all approaches in molecular imaging, the combination of near-infrared fluorescence imaging (NIRF) with radioisotopic imaging (PET or SPECT) allows one to benefit from the advantages of each of the imaging techniques, which are very complementary and of comparable sensitivity. To this end, the construction of monomolecular multimodal probes (MOMIP) has made it possible to combine the two imaging modalities within the same molecule, thus limiting the number of bioconjugation sites and yielding more homogeneous conjugates compared with those prepared through sequential conjugation. However, in order to optimize the bioconjugation strategy and, at the same time, the pharmacokinetic and biodistribution properties of the resulting imaging agent, a site-specific approach may be preferred. To further investigate this hypothesis, random and glycan-based site-specific bioconjugation approaches were compared thanks to a SPECT/NIRF bimodal probe based on an aza-BODIPY fluorophore. The overall experiments conducted and on HER2-expressing tumors demonstrated a clear superiority of the site-specific approach to improve affinity, specificity, and biodistribution of the bioconjugates.
Référence
Bioconjug Chem. 2023 03 27;:
